Treatment of active and postactive ileal and colonic Crohn's disease with oral pH-modified-release budesonide

Hepato-Gastroenterology

Volumn 44, Issue 14, 1997, Pages 445-451

  Caesar, I ^b   Gross, V ^b   Roth, M ^b   Andus, T ^b   Schmidt, C ^b   Raedsch, R ^b   Weber, A ^b   Gierend, M ^b   Ewe, K ^b   Scholmerich J ^a  

^a UNIVERSITY HOSPITAL REGENSBURG   (Germany)

^b NONE

Author keywords

Budesonide; Crohn's disease; Topical steroids

Indexed keywords

BUDESONIDE; GLUCOCORTICOID;

ABDOMINAL PAIN; ADULT; ARTICLE; ASCENDING COLON; CLINICAL TRIAL; COLON CROHN DISEASE; CROHN DISEASE; DISEASE ACTIVITY; DRUG EFFICACY; DRUG RELEASE; DRUG SAFETY; FEMALE; HEADACHE; HUMAN; ILEUM; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; REMISSION;

ADMINISTRATION, ORAL; ADULT; ANTI-INFLAMMATORY AGENTS; BUDESONIDE; COLONIC DISEASES; CROHN DISEASE; FEMALE; FOLLOW-UP STUDIES; GLUCOCORTICOIDS; HUMANS; HYDROGEN-ION CONCENTRATION; ILEAL DISEASES; LIVER; MALE; PREGNENEDIONES; REMISSION INDUCTION; SAFETY; TIME FACTORS; TREATMENT OUTCOME;

EID: 8244219684     PISSN: 01726390     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (16)

1. Malchow H, Ewe K, Brandes JW, et al. European Cooperative Crohn's Disease Study (ECDDS): Results of drug treatment. Gastroenterolgy 1984; 86: 249-266.
2. Summers RW, Switz DM, Sessions JT Jr, et al. National cooperative Crohn's disease study: Results of drug treatment. Gastroenterology 1979; 77: 847-869.
3. Brattsand R. Overview of newer glucocorticoid preparations for inflammatory bowel disease. Can J Gastroenterol 1990; 4: 407-414.
4. Matzen P and the Danish Budesonide Group. Budesonide enema in ulcerative colitis. A randomized dose-response trial with prednisolone enema as a positive control. Scand J Gastroenterol 1991; 26: 1225-1230.
5. Best WR, Becktel JM, Singleton JW, et al. Development of a Crohn's disease activity index: national co-operative Crohn's disease study. Gastroenterology 1970; 70: 439-444.
6. Möllmann H W, Barth J, Hochhaus G, et al. Grundlagen der Glukokortikoidtherapie bei chronisch entzündlichen Darmerkrankungen: topische versus systemische Applikation. Glukokortikoidtherapie chronisch entzündlicher Darmerkrankungen-Von der Grundlage zur rationalen Therapie. Falk Foundation 1996: 69-90
7. Rutgeerts P, Löfberg R, Malchow H, et al. A comparison of budesonide with prednisolone for active Crohn's disease. N Engl J Med 1994; 331: 842-845.
8. Gross V, Andus T, Caesar I, et al. Oral pH-modified release budesonide versus 6-methylprednisolone in active Crohn's disease. Eur.J.Gastroenterol. Hepatol. 1996; 8: 905-910
9. Greenberg GR, Feagan BG, Martin F, et al. Oral budesonide for active Crohn's disease. N Engl J Med 1994; 331: 836-841.
10. Campieri M, Ferguson A, Doe W. Oral budesonide competes favourably with prednisolone in active Crohn's disease. Gastroenterology 1995; 108: A 290
11. Löfberg R, Danielsson A, Salde L. Budesonide in active Crohn's disease. Aliment Pharmacol Ther 1993; 7: 611-616.
12. Löfberg R, Rutgeerts P, Malchow H et al. Budesonide prolongs time to relapse in ideal and ileocoecal Crohn's disease. A placebo controlled one year study. GUT 1996; 39:82-86.
13. Greenberg GR, Feagan BG, Martin F, et al. Oral budesonide as maintenance treatment for Crohn's disease. A placebo-controlled, dose-ranging study. Gastroenterology 1995; 110: 45-51.
14. Novacek G, Kleinberger M, Vogelsang H, et al. Budesonide in glucocorticoid dependent chronic active Crohn's disease; a pilot study. Z Gastroenterol 1995; 33: 251-254.
15. Caesar I, Gross V, Roth M, et al. Treatment of active Crohn's ileocolitis with oral pH-modified Budesonide. Z Gastroenterol 1995; 33: 247-250.
16. Roth M, Gross V, Ueberschaer B, et al. Treatment of active Crohn's disease with an oral slow release budesonide formulation. Am J Gastroenterol 1993; 88: 968-969.